Autolus Therapeutics PLC
AUTL
查看详细走势图
1.420USD
+0.100+7.58%
收盘 02/06, 16:00（美东）报价延迟15分钟
377.92M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+7.58%
5天
+3.65%
1月
-27.18%
6月
-39.57%
今年开始到现在
-28.64%
1年
-30.05%
查看详细走势图
TradingKey Autolus Therapeutics PLC股票评分
单位: USD 更新时间: 2026-02-06操作建议
Autolus Therapeutics PLC当前公司基本面数据相对稳定，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名44/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价8.99。中期看，股价处于平稳状态。近一个月，市场表现非常差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Autolus Therapeutics PLC评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看好
Autolus Therapeutics PLC亮点
亮点风险
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.
业绩高增长
公司营业收入稳步增长，连续3年增长59.12%
业绩增长期
公司处于发展阶段，最新年度总收入10.12M美元
利润高增长
公司净利润处于行业前列，最新年度总收入10.12M美元
估值高估
公司最新PE估值-1.69，处于3年历史高位
机构加仓
最新机构持股194.47M股，环比增加0.07%
景顺投资公司持仓
明星投资者景顺投资公司持仓，最新持仓市值38.05K
活跃度增加
近期活跃度增加，过去20天平均换手率0.62
分析师目标
根据
11
位分析师
买入
评级
8.990
目标均价
+551.45%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Autolus Therapeutics PLC新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Autolus Therapeutics PLC简介
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.
公司代码AUTL
公司Autolus Therapeutics PLC
CEOItin (Christian Martin)
网址https://www.autolus.com/
相关品种
